Zacks.com on MSN3d
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
Nasdaq3d
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Idexx Laboratories (IDXX)
Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...
BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Seeking Alpha4d
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Zacks.com on MSN1d
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
ETF Daily News5d
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a research note published on Friday, MarketBeat Ratings reports.